

# Emir Salas Sarduy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7041777/publications.pdf>

Version: 2024-02-01

20  
papers

196  
citations

1163117

8  
h-index

1058476

14  
g-index

21  
all docs

21  
docs citations

21  
times ranked

327  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes. <i>Scientific Reports</i> , 2017, 7, 12073.	3.3	27
2	An immunoenzymatic solid-phase assay for quantitative determination of HIV-1 protease activity. <i>Analytical Biochemistry</i> , 2002, 307, 18-24.	2.4	23
3	In silico Guided Drug Repurposing: Discovery of New Competitive and Non-competitive Inhibitors of Falcipain-2. <i>Frontiers in Chemistry</i> , 2019, 7, 534.	3.6	23
4	High-level expression of Falcipain-2 in <i>Escherichia coli</i> by codon optimization and auto-induction. <i>Protein Expression and Purification</i> , 2012, 83, 59-69.	1.3	20
5	Synthetic compounds from an <i>in house</i> library as inhibitors of falcipain-2 from <i>Plasmodium falciparum</i> . <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 30, 299-307.	5.2	20
6	Antiparasitic effect of a fraction enriched in tight-binding protease inhibitors isolated from the Caribbean coral <i>Plexaura homomalla</i> . <i>Experimental Parasitology</i> , 2013, 135, 611-622.	1.2	15
7	<i>DNA</i> damage inducible protein 1 is a conserved metacaspase substrate that is cleaved and further destabilized in yeast under specific metabolic conditions. <i>FEBS Journal</i> , 2018, 285, 1097-1110.	4.7	10
8	Intensity fading MALDI-TOF mass spectrometry and functional proteomics assignments to identify protease inhibitors in marine invertebrates. <i>Journal of Proteomics</i> , 2017, 165, 75-92.	2.4	8
9	Evaluation of quinoxaline compounds as ligands of a site adjacent to S2 (AS2) of cruzain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2197-2202.	2.2	8
10	Identification of Tight-Binding Plasmepsin II and Falcipain 2 Inhibitors in Aqueous Extracts of Marine Invertebrates by the Combination of Enzymatic and Interaction-Based Assays. <i>Marine Drugs</i> , 2017, 15, 123.	4.6	7
11	A heterogeneous enzymatic assay for quantification of Plasmepsin II activity and the evaluation of its inhibitors. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 34, 833-840.	2.8	6
12	Identification of (4-(9H-fluoren-9-yl) piperazin-1-yl) methanone derivatives as falcipain 2 inhibitors active against <i>Plasmodium falciparum</i> cultures. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 2911-2923.	2.4	6
13	In silico identification of noncompetitive inhibitors targeting an uncharacterized allosteric site of falcipain-2. <i>Journal of Computer-Aided Molecular Design</i> , 2021, 35, 1067-1079.	2.9	5
14	Rational design and synthesis of affinity matrices based on proteases immobilized onto cellulose membranes. <i>Preparative Biochemistry and Biotechnology</i> , 2017, 47, 745-753.	1.9	4
15	Computer-aided design of bromelain and papain covalent immobilization. <i>Revista Colombiana De Biotecnología</i> , 2014, 16, 19.	0.2	3
16	Potent and selective inhibitors for M32 metallo-carboxypeptidases identified from high-throughput screening of anti-kinetoplastid chemical boxes. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007560.	3.0	3
17	Tetracycline Derivatives Inhibit Plasmodial Cysteine Protease Falcipain-2 through Binding to a Distal Allosteric Site. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 159-175.	5.4	3
18	Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds. <i>Current Medicinal Chemistry</i> , 2019, 26, 6672-6686.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Efficient expression systems for cysteine proteases of malaria parasites. <i>Bioengineered</i> , 2013, 4, 107-114.	3.2	1
20	Screening and Identification of Metacaspase Inhibitors: Evaluation of Inhibition Mechanism and Trypanocidal Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	1